4 research outputs found
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum samples of 51 CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic markers, using Olink technology. Median event-free survival (EFS) was 23 months (range: 1.25–60.9). Patients with high levels of sCD23 (>11.27, p = 0.026), sCD27 (>11.03, p = 0.04), SPINT1 (>1.6, p = 0.001), and LY9 (>8.22, p = 0.0003) had a shorter EFS than those with marker levels below the median. The effect of sCD23 on EFS differed between immunoglobulin heavy chain variable gene-mutated and unmutated patients, with the shortest EFS for unmutated CLL patients with sCD23 levels above the median. Taken together, our results validate the prognostic impact of sCD23 and highlight SPINT1 and LY9 as possible promising markers for treatment response in CLL patients
Relative survival reaches a plateau in hairy cell leukemia: A population-based analysis in The Netherlands
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study
Recently the Belgium-Dutch Hematology-Oncology group initiated a
multicenter study to evaluate whether myeloma patients treated with
intensive chemotherapy benefit from additional peripheral stem cell
transplantation. To determine treatment response accurately, we decided to
quantitate malignant cells. To test a consensus quantitation strategy, 5
centers independently determined the immunoglobulin heavy chain sequences
of patient tumor cells and developed allele-specific oligonucleotides
(ASO) and ASO-polymerase chain reaction (PCR). We compared the
reproducibility of real-time quantitation with quantitation using limiting
dilutions. We distributed DNA samples with a 4-log range of tumor cell
concentrations and found average quantitation values deviating 74% and 42%
from the input values with real-time PCR (1 center) and limiting dilutions
(4 centers), respectively. Within single centers we found an average
variation coefficient of 0.74, with limiting dilutions not significantly
different from the average 0.82 center-to-center variation coefficient.
Within a single center, real-time quantitation proved more reproducible
(average variation coefficient, 0.36). Quantification was confirmed in 3
patients during treatment in the protocol. This report shows that
real-time PCR or limiting dilution assays can be used for quantitation in
a single multicenter trial. We present a consensus strategy that allows an
accurate comparison of quantitation data generat